Search

Your search keyword '"Miquel Pujol"' showing total 6 results
Start Over Author "Miquel Pujol" Publisher oxford university press (oup)
6 results on '"Miquel Pujol"'

1. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort

Author

Antonio Sánchez-Porto, Jesús Rodríguez-Baño, Luis Eduardo López-Cortés, Maria Tomas, Álvaro Pascual Hernández, Simona Mihaela Iftimie, Jordi Vila, German Bou, Miquel Pujol, Jerónimo Pachón, Luis Martínez Martínez, María de la Luz Cádiz-Gurrea, Teresa Nebreda-Mayoral, José Miguel Cisneros, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, and Azucena Rodriguez-Guardado

Subjects
Pharmacology, Microbiology (medical), medicine.medical_specialty, Carbapenem, Combination therapy, biology, business.industry, Subgroup analysis, Tigecycline, medicine.disease, biology.organism_classification, Surgery, Acinetobacter baumannii, Sepsis, Infectious Diseases, Internal medicine, medicine, Colistin, Pharmacology (medical), Prospective cohort study, business, medicine.drug
Abstract

Results: One hundred and one patients were included in the analysis; 68 (67.3%) received MT and 33 (32.7%) received CT. Pneumonia was the most common infection (50.5%), 68.6% of cases being associated with mechanical ventilation. Colistin (67.6%) and carbapenems (14.7%) were the most common drugs used in MT; colistin plus tigecycline (27.3%) and carbapenem plus tigecycline (12.1%) were the most frequent combinations. Crude 30 day mortality was 23.5% and 24.2% for the MT and CT groups, respectively (RR ¼ 1.03; 95% CI 0.49 – 2.16; P ¼ 0.94). Multivariate analysis of 30 day survival showed no trend towards reduced 30 day mortality with CT (HR ¼1.35; 95% CI 0.53–3.44; P ¼ 0.53). Subgroup analysis showed similar results. Conclusions: Our data do not support an association of CT with reduced mortality in MDRAB infections. More data for specific types of infection and combinations are needed.

Published
2014
Full Text
View/download PDF

2. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin

Author

I. Olarte, J. Torre-Cisneros, José Miguel Montejo, E. Bereciertua, Juan Pablo Horcajada, R. Sordé, Vicente Pintado, Ana Arnaiz, Emilio Ojeda, Margarita Salvadó, G. García-Pardo, Miquel Pujol, Francisco López-Medrano, José Antonio Lepe, Miguel Sánchez García, M. Xercavins, Fernando Rodríguez-López, Fernando Barcenilla, Belén Padilla, Álvaro Pascual, F. Marco, Oriol Gasch, E. Cercenado, José Molina, Milagro Montero, Jesús Rodríguez-Baño, René Unda Lara, Nieves Larrosa, María Lagarde, C. Dueñas, María Ángeles Domínguez, María Cruz Rodríguez, J A Martínez, Javier Murillas, Clara Natera, Geih Study Groups, J. M. García-Arenzana, A. Goenaga, Luis Eduardo López-Cortés, Benito Almirante, Fernando Chaves, Cristina Fernández, M. Á. von Wichmann, Elena Loza, E. Ruiz de Gopegui, José L. Hernández, H. Espejo, C. Martin, A. Granados, G. García-Prado, J. Tapiol, Mariana Camoez, C. Padilla, D. Fontanals, Beatriz Mirelis, N. Benito, José Ramón Blanco, Esther Calbo, A. Jover, and M. A. Morera

Subjects
Adult, Male, Methicillin-Resistant Staphylococcus aureus, Microbiology (medical), Bacteremia, medicine.disease_cause, Microbiology, Cohort Studies, Daptomycin, Drug Resistance, Multiple, Bacterial, medicine, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, business.industry, Middle Aged, Staphylococcal Infections, Methicillin-resistant Staphylococcus aureus, Anti-Bacterial Agents, Treatment Outcome, Infectious Diseases, Cohort, Female, business, Follow-Up Studies, medicine.drug
Published
2013
Full Text
View/download PDF

3. LB3. Daptomycin Plus Fosfomycin vs. Daptomycin Monotherapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Multicenter, Randomized, Clinical Trial

Author

Luis Eduardo López-Cortés, Joaquín López-Contreras, Miquel Pujol, Jordi Carratalà, Rosa Escudero, J. Càmara, Natalia Pallares, Esther Calbo, Oriol Gasch, Mireia Puig, Alfredo Jover, Rafael San Juan Garrido, Miró Jm, Evelyn Shaw, Ariadna Padullés, Sebastián Videla, José María Aguado, Carle Pigrau, G. García-Pardo, Cristian Tebé, Mireia Sanllorente, Pilar Hereu, Maria Jose Garcia-Pais, Juan Pasquau, Marta Andrés, Vicente Pintado, María Ángeles Domínguez, Laura Morata, Milagro Montero, Regino Rodriguez, Belén Padilla, Javier Murillas, and José Miguel Montejo

Subjects
0301 basic medicine, medicine.medical_specialty, Surrogate endpoint, business.industry, 030106 microbiology, Fosfomycin, medicine.disease_cause, medicine.disease, Methicillin-resistant Staphylococcus aureus, law.invention, Abstracts, 03 medical and health sciences, Infectious Diseases, Oncology, Randomized controlled trial, law, Internal medicine, Bacteremia, medicine, Combined Modality Therapy, Daptomycin, C. Late Breaker Abstracts, Adverse effect, business, medicine.drug
Abstract

Background Daptomycin plus fosfomycin combination has demonstrated synergistic and bactericidal effect in animal models of methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but there is lack of data in humans. Method A randomized (1:1), open-label, clinical trial involving adults with MRSAB was conducted at 18 medical centers in Spain. Patients were assigned to receive daptomycin, 10 mg/kg IV daily plus fosfomycin, 2 g IV/6 hour (combination therapy) or to receive daptomycin 10 mg/kg/24 h IV (monotherapy) during 10 up to 14 days for uncomplicated bacteremia and 28 up to 42 days for complicated bacteremia. The primary efficacy endpoints were: (a) treatment success at Test-of-Cure visit (ToC: 6 weeks after end of therapy) and (b) treatment success at 7 days (defined as alive at day 7 and clearance of bacteremia without relapse from 8 to 90 days after randomization), according with the proposed primary endpoints for use in clinical trials in bloodstream infections in adults. Result Between December 2013 and November 2017, 674 patients with MRSAB were evaluated and 155 patients were randomized: 74 received combination therapy and 81 monotherapy. In intention-to-treat analysis, (a) at ToC visit successful outcome was achieved in 40 of 74 patients (54,1%) who received combination therapy as compared with 34 of 81 patients (42%) who were given monotherapy (54.1% vs. 42.0%; absolute difference, 12.1%; 95% confidence interval, 0%-27.0%); (b) at 7 days after starting the therapy: a successful outcome was achieved in 69 of 74 patients who received combination therapy as compared with 62 out of 81 patients who received monotherapy (93.2% vs. 76.5%; absolute difference, 16.7%; 95% confidence interval, 5.4%–27.7%). Combination therapy was associated with lower rates of microbiologic failure than monotherapy at ToC visit (0 vs. 9 patients, P = 0.009). Combination therapy, as compared with daptomycin monotherapy, was associated with a nonsignificantly higher rate of adverse events due to study medication leading to treatment failure and discontinuation of therapy: 6/74 (8.1%) vs. 3/81 (3.7%) (P = 0.31). Conclusion The combination of daptomycin plus fosfomycin was more effective than daptomycin alone for treating MRSAB (NCT01898338). Disclosures All authors: No reported disclosures.

Published
2018
Full Text
View/download PDF

4. Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system*

Author

Mosqueda, Noraida, primary, Gato, Eva, additional, Roca, Ignasi, additional, López, María, additional, de Alegría, Carlos Ruíz, additional, Fernández Cuenca, Felipe, additional, Martínez-Martínez, Luis, additional, Pachón, Jerónimo, additional, Cisneros, José Miguel, additional, Rodríguez-Baño, Jesús, additional, Pascual, Álvaro, additional, Vila, Jordi, additional, Bou, Germán, additional, Tomás, María, additional, Garnacho, José, additional, Pizarraya, Antonio Gutierrez, additional, Márquez Vácaro, Juan Antonio, additional, Cano, María Eliecer, additional, Fariñas, M. Carmen, additional, Porto, Antonio Sánchez, additional, Meruendano, Gloria Esteban, additional, Vales, Luis Barbeyto, additional, Ciria, Javier Casas, additional, Vallejo, Luis, additional, Pérez, Begona Fernández, additional, Chao, José Carlos Villar, additional, Ortega, Belén Padilla, additional, Mansilla, Emilia Cercenado, additional, Irure, José Javier García, additional, del Arco Jiménez, Alfonso, additional, Cardona, Concepción Gimeno, additional, Valía, Juan Carlos, additional, Palop, Núria Tormo, additional, Abril, Vicente, additional, Rifa, Josefina, additional, Jesus, Maria, additional, Garcia, Martinez, additional, Pujals, Joseph Vilaró, additional, Aguirre, Marian Navarro, additional, Vilamala, Ana, additional, Alfaro, José Antonio Jiménez, additional, Jaca, Carlos Reviejo, additional, Casanova, Pilar Marín, additional, Guerreo, Francisca, additional, Shaw, Evelyn, additional, Plasencia, Virginia, additional, Mayoral, Teresa Nebreda, additional, Calavia, María José Fernández, additional, de Cruz, Susana García, additional, Mansilla, Carmen Aldea, additional, de Lucas, Esperanza Merino, additional, Zorraquino, Alfredo, additional, Bañuls, Sergio Reus, additional, Eseverri, Eugenio Garduno, additional, Sánchez, Luis López, additional, Gutiérrez, Ana Fleites, additional, Guardado, Azucena Rodríguez, additional, Moreno, Alfonso, additional, Anguera, José María García-Arenzana, additional, Palmero, Serafín López, additional, Maresca, Manuel Rodríguez, additional, Garrote, Fernando García, additional, Otero, José Varela, additional, del Pilar Alonso, María, additional, Verdú, Elisa Vidal, additional, López, Fernando Rodríguez, additional, Sánchez, Fernanda Pardo, additional, Vizoso, E. Ferrer, additional, Garcia, B. Regueiro, additional, Gurgui, Mercé, additional, Pericas, Roser, additional, Pomar, Virginia, additional, Astigarraga, Pedro María Olaechea, additional, Igartua, Rafael Ayarza, additional, Romero, María Dolores Maciá, additional, de Gopegui Bordes, Enrique Ruiz, additional, Romero, María Isabel Sánchez, additional, Mata, Jesús García, additional, Goyanes, María José, additional, Mateos, Cristina Morales, additional, Quero, José Hernández, additional, Lara, Trinidad Escobar, additional, Bastardie, Frederic Ballester, additional, Iftimie, Simona, additional, Bajador, Isabel Pujol, additional, Navarro, María Isabel Galán, additional, Gurrea, María Luz Cádiz, additional, Antequera, Carmen Amores, additional, Gómez, Montserrat, additional, Cantudo, Purificación, additional, Salas, Carmina Martí, additional, Peragosa, Jordi Cuquet, additional, Flores, Antonio Moreno, additional, García, Luis Anibarro, additional, Real, Susana Hernando, additional, González, Pablo A. Carrero, additional, González, María Angeles Pallarés, additional, Fernández, Sergio Rodríguez, additional, Rojo, Miquel Pujol, additional, Tubau, Fe, additional, Alvarez, Enrique Nuno, additional, Torres, María Ortega, additional, Almaraz, Salvador Giner, additional, Castelló, María Rosa Roca, additional, Castillo, Manuela, additional, Hortelano, Elena, additional, Sánchez, Fernando Chaves, additional, Reyne, Ana García, additional, Gallego, Juan Pablo Horcajada, additional, Segura, Concha, additional, Dorado, Gema Sierra, additional, Escudero, Raquel Yano, additional, Hung, María Elena Dorta, additional, and del Rosario Q, Cristóbal, additional

Published
2014
Full Text
View/download PDF

6. Prognosis of Enterococcal Endocarditis

Author

M. Gurgui, B. Almirante, J. M. Miró, M. P. Tornos, and Miquel Pujol

Subjects
Microbiology (medical), medicine.medical_specialty, Infectious Diseases, business.industry, Medicine, business, Intensive care medicine, Enterococcal endocarditis
Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results